Last reviewed · How we verify
fesoterodine 8mg
Fesoterodine 8mg, marketed by the University of Alberta, is an established treatment in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence and the protection offered by its patent. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | fesoterodine 8mg |
|---|---|
| Also known as | Toviaz 8mg |
| Sponsor | University of Alberta |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment (PHASE2)
- Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children. (PHASE3)
- Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children (PHASE3)
- An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia (PHASE4)
- InSite for Over Active Bladder (PHASE4)
- Comparison Between Desmopressin and Fesoterodine for Treatment of Night Time Voiding in Women Aged 65 and Older (PHASE2, PHASE3)
- Validation of Instruments for Pragmatic Clinical Trials for Overactive Bladder (PHASE1)
- A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fesoterodine 8mg CI brief — competitive landscape report
- fesoterodine 8mg updates RSS · CI watch RSS
- University of Alberta portfolio CI